Intravenous Infusions Plc (GHSE:IIL)
0.0800
0.00 (0.00%)
At close: Jun 2, 2026
Intravenous Infusions Balance Sheet
Financials in millions GHS. Fiscal year is January - December.
Millions GHS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.02 | 1.49 | 0.29 | 0.95 | 0.81 |
Cash & Short-Term Investments | 0.02 | 1.49 | 0.29 | 0.95 | 0.81 |
Cash Growth | -98.59% | 405.98% | -69.17% | 18.07% | -16.05% |
Accounts Receivable | 4.93 | 10.23 | 15.07 | 15.13 | 15.74 |
Other Receivables | 2.62 | 2.41 | 1.44 | 1.77 | 1.79 |
Receivables | 7.55 | 12.63 | 16.51 | 16.9 | 17.53 |
Inventory | 4.53 | 6.09 | 6.26 | 6.63 | 7.65 |
Prepaid Expenses | 0.44 | 0.06 | 0.09 | 0.07 | 0.09 |
Total Current Assets | 12.55 | 20.26 | 23.15 | 24.55 | 26.08 |
Property, Plant & Equipment | 25.88 | 24.5 | 23.26 | 22.21 | 20.41 |
Long-Term Investments | 0.01 | 0.01 | 0.01 | - | - |
Other Intangible Assets | 0.06 | 0.07 | 0.07 | 0.06 | 0.06 |
Long-Term Deferred Tax Assets | 0.6 | - | - | - | - |
Total Assets | 39.09 | 44.84 | 46.49 | 46.82 | 46.55 |
Accounts Payable | 8.49 | 12.21 | 9.33 | 8.52 | 7.1 |
Accrued Expenses | 0.07 | 0.05 | 0.18 | 0.18 | 0.2 |
Short-Term Debt | 0.42 | 0.87 | 1.23 | 1.64 | - |
Current Portion of Long-Term Debt | 3.94 | 3.94 | 3.94 | 4.09 | 2.54 |
Current Portion of Leases | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
Current Income Taxes Payable | - | - | 0 | - | - |
Other Current Liabilities | 9.48 | 7.31 | 6.15 | 6.96 | 4.15 |
Total Current Liabilities | 22.43 | 24.4 | 20.86 | 21.4 | 14 |
Long-Term Debt | 5.35 | 3.94 | 7.88 | 10.36 | 13.81 |
Long-Term Leases | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Long-Term Deferred Tax Liabilities | - | 0.55 | 0.39 | 0.25 | 0.41 |
Total Liabilities | 27.81 | 28.93 | 29.17 | 32.04 | 28.26 |
Common Stock | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 |
Additional Paid-In Capital | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
Retained Earnings | -2.45 | 2.18 | 3.59 | 1.05 | 4.56 |
Shareholders' Equity | 11.28 | 15.91 | 17.32 | 14.78 | 18.29 |
Total Liabilities & Equity | 39.09 | 44.84 | 46.49 | 46.82 | 46.55 |
Total Debt | 9.77 | 8.81 | 13.12 | 16.13 | 16.39 |
Net Cash (Debt) | -9.75 | -7.32 | -12.83 | -15.18 | -15.58 |
Net Cash Per Share | -0.04 | -0.03 | -0.05 | -0.06 | -0.06 |
Filing Date Shares Outstanding | 274.41 | 274.41 | 274.41 | 274.41 | 274.41 |
Total Common Shares Outstanding | 274.41 | 274.41 | 274.41 | 274.41 | 274.41 |
Working Capital | -9.88 | -4.14 | 2.29 | 3.15 | 12.08 |
Book Value Per Share | 0.04 | 0.06 | 0.06 | 0.05 | 0.07 |
Tangible Book Value | 11.22 | 15.84 | 17.25 | 14.72 | 18.23 |
Tangible Book Value Per Share | 0.04 | 0.06 | 0.06 | 0.05 | 0.07 |
Land | 3.74 | 3.74 | 3.74 | 3.74 | 2.66 |
Machinery | 8.79 | 8.79 | 8.74 | 5.59 | 5.48 |
Construction In Progress | 20.05 | 18.12 | 16.31 | 17.63 | 16.41 |